Vyas J, Johns J R, Abdelrazik Y, Ali F M, Ingram J R, Salek S, Finlay A Y
Centre for Medical Education, School of Medicine, Cardiff University, Cardiff, UK.
Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
J Eur Acad Dermatol Venereol. 2025 Mar;39(3):631-679. doi: 10.1111/jdv.20321. Epub 2024 Sep 13.
The validation of psychometric measures requires use of other established and standardized validated measures. The Dermatology Life Quality Index (DLQI) is the most widely used tool to measure the burden of skin diseases and assess effectiveness of interventions based on patients' perspective.
The objective of this study was to systematically analyse peer-reviewed publications describing use of the DLQI in validation of other patient-reported outcome (PRO) and quality-of-life (QoL) measures.
Seven databases were searched for papers published between January 1994 and December 2022 for articles containing data using DLQI in the validation of other PRO/QoL measures. The methodology followed PRISMA guidelines. The protocol was prospectively registered on PROSPERO.
Of 1717 screened publications, 122 articles including 30,727 patients from 34 different countries with 41 diseases met the inclusion criteria. The DLQI was used in validation of 101 measures: 80 dermatology-specific QoL measures, mostly disease-specific, and 21 generic measures. Of these studies, 47 were cross-cultural adaptations, 116 single arm, 100 were cross-sectional, 18 longitudinal and six randomized placebo controlled. DLQI was used for 14 known group, and correlation for 10 construct, 101 convergent, 10 concurrent, 10 divergent/discriminant and three criterion validity tests using Mann-Whitney (2), Spearman's (80), Pearson's correlation (26) and Student's t-test (1). The DLQI was used in responsiveness analysis in 13 studies.
This review identified widespread use of the DLQI in validation of other dermatology PRO/QoL measures and confirmed the central role that the DLQI plays as a benchmark in instrument development and validation across dermatology and beyond. The use of the DLQI by so many developers of other instruments has provided a common standard for comparability.
心理测量方法的验证需要使用其他已确立的、标准化的经过验证的方法。皮肤病生活质量指数（DLQI）是用于衡量皮肤病负担并从患者角度评估干预措施有效性的最广泛使用的工具。
本研究的目的是系统分析同行评审的出版物，这些出版物描述了DLQI在验证其他患者报告结局（PRO）和生活质量（QoL）测量方法中的应用。
检索了七个数据库，查找1994年1月至2022年12月期间发表的论文，以获取在验证其他PRO/QoL测量方法中使用DLQI数据的文章。该方法遵循PRISMA指南。该方案已在PROSPERO上进行前瞻性注册。
在1717篇筛选出的出版物中，122篇文章符合纳入标准，这些文章来自34个不同国家，共纳入30727例患有41种疾病的患者。DLQI被用于验证101种测量方法：80种皮肤病特异性QoL测量方法，大多是疾病特异性的，以及21种通用测量方法。在这些研究中，47项是跨文化改编，116项是单臂研究，100项是横断面研究，18项是纵向研究，6项是随机安慰剂对照研究。DLQI用于14项已知组研究、10项结构效度、101项收敛效度、10项同时效度、10项发散/区分效度以及三项标准效度测试，采用了曼-惠特尼检验（2项）、斯皮尔曼相关分析（80项）、皮尔逊相关分析（26项）和学生t检验（1项）。DLQI在13项研究中用于反应性分析。
本综述确定了DLQI在验证其他皮肤病PRO/QoL测量方法中的广泛应用，并证实了DLQI在皮肤病及其他领域的工具开发和验证中作为基准所起的核心作用。众多其他工具开发者对DLQI的使用提供了可比性的通用标准。
Zotero 插件